A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

NCT06617416 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

560

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: Cadonilimab (AK104)
DRUG: Sugemalimab

Sponsor

Akeso